American Association for Cancer Research

Skip to Main Content

Table 3

Microsatellite analysis of clinical samples by N-stage of the tumor at the time of surgery^a

Sample (n = 28)	pN-Stage			P ^b
Sample (n = 28)		pN0 (n = 12)	pN1 (n = 16)	P ^b
Tumor LOH/SHIFT	10 (83.3)	16 (100)	0.17 n.s
Tumor 1–2	2 (16.7)	3 (18.8)	0.28 n.s
Tumor > 2	8 (66.7)	13 (81.3)	0.17 n.s
Serum LOH/SHIFT	11 (91.7)	16 (100)	0.42 n.s
Serum 1–2	3 (25)	5 (31.4)	0.44 n.s
Serum > 2	8 (66.7)	11 (68.8)	0.45 n.s

Sample (n = 28)	pN-Stage			P ^b
Sample (n = 28)		pN0 (n = 12)	pN1 (n = 16)	P ^b
Tumor LOH/SHIFT	10 (83.3)	16 (100)	0.17 n.s
Tumor 1–2	2 (16.7)	3 (18.8)	0.28 n.s
Tumor > 2	8 (66.7)	13 (81.3)	0.17 n.s
Serum LOH/SHIFT	11 (91.7)	16 (100)	0.42 n.s
Serum 1–2	3 (25)	5 (31.4)	0.44 n.s
Serum > 2	8 (66.7)	11 (68.8)	0.45 n.s

^a

Number (%) of LOH or SHIFT in the sample according to N-stage.

^b

Two-sided Fisher’s exact test.